FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201609139> ?p ?o ?g. }

• W3201609139 endingPage "86" @default.
• W3201609139 startingPage "78" @default.
• W3201609139 abstract "Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective for glycemic control and have demonstrated cardiorenal benefits. The U.S. Food and Drug Administration (FDA) released a boxed warning in 2018 regarding the potential development of Fournier’s gangrene (FG) with the use of SGLT2 inhibitors. FG is a serious perineal infection with a mortality rate of up to 88% in some cases. Objectives To report spontaneous post-marketing cases from the FDA Adverse Event Reporting System (FAERS) database and case reports from the literature of FG associated with the use of SGLT2 inhibitors and to determine whether correlations exist with specific agents. Methods A search of the FAERS database was conducted to identify reported cases of FG associated with the use of any FDA-approved SGLT2 inhibitor between 1 March 2013 and 30 June 2020. Additionally, a literature search was conducted of PubMed, Embase, and the Cochrane library using PRISMA guidelines to identify case reports of FG with the use of SGLT2 inhibitors up to 9 October 2020. Results A total of 491 cases from the FAERS database were included for review. Descriptive analysis depicted more cases in the empagliflozin, canagliflozin, and dapagliflozin groups than in the ertugliflozin group. Nine case reports were included from the literature review; four attributed to dapagliflozin, three to empagliflozin, and two to canagliflozin. The median ages from cases reported in the FAERS database and from the literature review were 54 and 52 years, respectively. In both datasets, males had a higher incidence of FG than females. Additional data reported include clinical outcomes and concomitant antihyperglycemic medications. Conclusion Consistent findings are noted in this systematic review and warrant further investigation to elucidate the association between SGLT2 inhibitor use and the development of FG. These results may drive enhanced prescribing patterns to consider patient-specific risk factors and timely monitoring, especially as more indications are approved related to these medications’ cardiorenal protective properties." @default.
• W3201609139 created "2021-09-27" @default.
• W3201609139 creator A5002960166 @default.
• W3201609139 creator A5083284001 @default.
• W3201609139 creator A5084472855 @default.
• W3201609139 date "2022-01-01" @default.
• W3201609139 modified "2023-10-16" @default.
• W3201609139 title "Sodium–Glucose Cotransporter 2 Inhibitor Use Associated With Fournier’s Gangrene: A Review of Case Reports and Spontaneous Post-Marketing Cases" @default.
• W3201609139 cites W1974864689 @default.
• W3201609139 cites W2012716861 @default.
• W3201609139 cites W2031657251 @default.
• W3201609139 cites W2051366291 @default.
• W3201609139 cites W2093750746 @default.
• W3201609139 cites W2096602482 @default.
• W3201609139 cites W2104747643 @default.
• W3201609139 cites W2146264128 @default.
• W3201609139 cites W2148865914 @default.
• W3201609139 cites W2351709562 @default.
• W3201609139 cites W2560438049 @default.
• W3201609139 cites W2619772777 @default.
• W3201609139 cites W2626446274 @default.
• W3201609139 cites W2751324783 @default.
• W3201609139 cites W2768838769 @default.
• W3201609139 cites W2770728129 @default.
• W3201609139 cites W2788574161 @default.
• W3201609139 cites W2791105808 @default.
• W3201609139 cites W2900413769 @default.
• W3201609139 cites W2906872931 @default.
• W3201609139 cites W2944717765 @default.
• W3201609139 cites W2963242313 @default.
• W3201609139 cites W2975412902 @default.
• W3201609139 cites W2977736009 @default.
• W3201609139 cites W2981240019 @default.
• W3201609139 cites W2999296947 @default.
• W3201609139 cites W3001753139 @default.
• W3201609139 cites W3006084195 @default.
• W3201609139 cites W3015074668 @default.
• W3201609139 cites W3030232062 @default.
• W3201609139 cites W3041720083 @default.
• W3201609139 cites W3092379111 @default.
• W3201609139 cites W3159748447 @default.
• W3201609139 doi "https://doi.org/10.2337/cd21-0015" @default.
• W3201609139 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35221476" @default.
• W3201609139 hasPublicationYear "2022" @default.
• W3201609139 type Work @default.
• W3201609139 sameAs 3201609139 @default.
• W3201609139 citedByCount "5" @default.
• W3201609139 countsByYear W32016091392022 @default.
• W3201609139 countsByYear W32016091392023 @default.
• W3201609139 crossrefType "journal-article" @default.
• W3201609139 hasAuthorship W3201609139A5002960166 @default.
• W3201609139 hasAuthorship W3201609139A5083284001 @default.
• W3201609139 hasAuthorship W3201609139A5084472855 @default.
• W3201609139 hasBestOaLocation W32016091391 @default.
• W3201609139 hasConcept C126322002 @default.
• W3201609139 hasConcept C134018914 @default.
• W3201609139 hasConcept C197934379 @default.
• W3201609139 hasConcept C2775887513 @default.
• W3201609139 hasConcept C2777105317 @default.
• W3201609139 hasConcept C2777180221 @default.
• W3201609139 hasConcept C2777422806 @default.
• W3201609139 hasConcept C2777451236 @default.
• W3201609139 hasConcept C2779306644 @default.
• W3201609139 hasConcept C2781283889 @default.
• W3201609139 hasConcept C555293320 @default.
• W3201609139 hasConcept C71924100 @default.
• W3201609139 hasConceptScore W3201609139C126322002 @default.
• W3201609139 hasConceptScore W3201609139C134018914 @default.
• W3201609139 hasConceptScore W3201609139C197934379 @default.
• W3201609139 hasConceptScore W3201609139C2775887513 @default.
• W3201609139 hasConceptScore W3201609139C2777105317 @default.
• W3201609139 hasConceptScore W3201609139C2777180221 @default.
• W3201609139 hasConceptScore W3201609139C2777422806 @default.
• W3201609139 hasConceptScore W3201609139C2777451236 @default.
• W3201609139 hasConceptScore W3201609139C2779306644 @default.
• W3201609139 hasConceptScore W3201609139C2781283889 @default.
• W3201609139 hasConceptScore W3201609139C555293320 @default.
• W3201609139 hasConceptScore W3201609139C71924100 @default.
• W3201609139 hasIssue "1" @default.
• W3201609139 hasLocation W32016091391 @default.
• W3201609139 hasLocation W32016091392 @default.
• W3201609139 hasLocation W32016091393 @default.
• W3201609139 hasLocation W32016091394 @default.
• W3201609139 hasLocation W32016091395 @default.
• W3201609139 hasOpenAccess W3201609139 @default.
• W3201609139 hasPrimaryLocation W32016091391 @default.
• W3201609139 hasRelatedWork W2520711045 @default.
• W3201609139 hasRelatedWork W2624862988 @default.
• W3201609139 hasRelatedWork W2738105394 @default.
• W3201609139 hasRelatedWork W2928289028 @default.
• W3201609139 hasRelatedWork W3028807382 @default.
• W3201609139 hasRelatedWork W3029803913 @default.
• W3201609139 hasRelatedWork W3201609139 @default.
• W3201609139 hasRelatedWork W4220777946 @default.
• W3201609139 hasRelatedWork W4313236864 @default.
• W3201609139 hasRelatedWork W4380150609 @default.
• W3201609139 hasVolume "40" @default.
• W3201609139 isParatext "false" @default.

• next